- Home
- NBR vs SEPN Comparison
NBR vs SEPN Comparison
Compare NBR & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- SEPN
- Stock Information
- Founded
- NBR 1952
- SEPN 2022
- Country
- NBR Bermuda
- SEPN United States
- Employees
- NBR N/A
- SEPN 75
- Industry
- NBR Oil & Gas Production
- SEPN
- Sector
- NBR Energy
- SEPN
- Exchange
- NBR Nasdaq
- SEPN NYSE
- Market Cap
- NBR 498.6M
- SEPN 522.7M
- IPO Year
- NBR N/A
- SEPN 2024
- Fundamental
- Price
- NBR $30.37
- SEPN $12.61
- Analyst Decision
- NBR Hold
- SEPN Strong Buy
- Analyst Count
- NBR 8
- SEPN 5
- Target Price
- NBR $44.50
- SEPN $26.75
- AVG Volume (30 Days)
- NBR 523.7K
- SEPN 398.8K
- Earning Date
- NBR 07-29-2025
- SEPN 08-15-2025
- Dividend Yield
- NBR N/A
- SEPN N/A
- EPS Growth
- NBR N/A
- SEPN N/A
- EPS
- NBR N/A
- SEPN N/A
- Revenue
- NBR $2,932,608,000.00
- SEPN $977,000.00
- Revenue This Year
- NBR $13.65
- SEPN $3,429.67
- Revenue Next Year
- NBR $5.44
- SEPN N/A
- P/E Ratio
- NBR N/A
- SEPN N/A
- Revenue Growth
- NBR N/A
- SEPN 108.76
- 52 Week Low
- NBR $23.27
- SEPN $4.17
- 52 Week High
- NBR $105.96
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- NBR 50.92
- SEPN N/A
- Support Level
- NBR $29.50
- SEPN N/A
- Resistance Level
- NBR $35.66
- SEPN N/A
- Average True Range (ATR)
- NBR 1.95
- SEPN 0.00
- MACD
- NBR -0.13
- SEPN 0.00
- Stochastic Oscillator
- NBR 51.98
- SEPN 0.00
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.